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Abstract To assess the differences between melanomas of
different location and different etiology, 372 malignant
melanomas were brought in a tissue microarray format.
The collection included 23 acral and 118 non-acral skin
melanomas, 9 mucosal melanomas, 100 uveal melanomas,
and 122 melanoma metastases. Fluorescence in situ
hybridization (FISH) was used to assess copy number
changes of the cyclin D1 (CCND1), MDM2, c-myc
(MYC), and HER2 genes. FISH analysis revealed distinct
differences between melanomas from different locations.
CCND1 amplifications were detected in skin melanomas
from sites with chronic sun exposure (6 of 32 cases), acral
melanomas (4 of 17 cases), and mucosal melanomas (one
of ten cases) but not in uveal melanomas. High-level
MDM2 amplifications were exclusively present in acral
melanomas (2 of 19 cases). MYC copy number gains were
detected in 32 of 71 uveal melanomas, five of eight
mucosal melanomas, and 6 of 67 melanomas from sites
with intermittent sun exposure but not in acral melanomas
nor melanomas from sites with chronic sun exposure.
Alterations of the MYC gene were associated with
advanced tumor stage. There were no high-level HER2
amplifications. Site-specific genetic and epigenetic features
may impact the response of melanomas to various anti-
cancer drugs and should be considered in future studies on
the molecular pathogenesis of malignant melanomas.
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Introduction
There is considerable hope that a new generation of anti-
cancer drugs targeting specific genes or molecular path-
ways may be more efficient in the future. The introduction
of trastuzumab (Herceptin), a humanized antibody for the
treatment of HER2-positive metastatic breast cancer [9,
29], has pointed out the potential of molecular-targeted
therapy. As the results of systemic treatment with classical
cytostatic drugs in melanoma patients presenting distant
metastases have been discouraging with only a minority of
these patients living beyond 1 year [1]. The discovery of
frequent mutations of the BRAF gene in malignant
melanomas [13] and the subsequent development of
BRAF antagonists [7] have raised new hope. If individual
molecular features should be targeted in cancer cells,
melanoma subgroups with different molecular signatures
may be clinically important. It is interesting that there is
increasing evidence for distinct molecular characteristics of
melanoma subtypes depending on the localization and
different levels of sun exposure of the primary tumor [3, 5,
11, 12, 33, 37, 39, 42]. It is tempting to speculate that such
differences may be due to a site-specific etiology of
melanoma. For example, mutations of the BRAF gene have
been shown to be preferentially present in melanomas from
sites with intermittent sun exposure [12, 24] and acral
melanomas [33] but were nearly inexistent in tumors
arising in sites of chronic sun-induced damage, mucosal
melanomas [15], and uveal melanomas [10, 14]. Gene
amplifications were found to be significantly more frequent
in acral and mucosal melanomas than in melanomas from
non-acral skin [3, 12]. In addition to the site-specific
differences in the degree of genomic instability, there is
increasing evidence of distinct patterns of genetic altera-
tions depending on the localization of the primary tumor
[12, 41].
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To collect more information on possible site-specific
molecular differences, we determined the frequency of
amplifications of the proto-oncogenes cyclin D1 (CCND1),
MDM2, c-myc (MYC), and HER2 in melanomas from
different localizations including mucosal and uveal mela-
nomas. For the purpose of this study, we selected a tissue
microarray format which allowed us to analyze a total of
372 melanomas on one tissue slide under highly stan-
dardized experimental conditions.
Materials and methods
Tumors
Formalin-fixed and paraffin-embedded tissues from 141
primary skin melanomas, 100 uveal melanomas, 9 mucosal
melanomas, and 122 metastases (70 lymph node and 52
hematogenous) were brought in a tissue microarray (TMA)
format [21]. Primary tumors and corresponding metastases
were available from 16 patients and more than one
metastasis from 12 patients. Among the 141 primary skin
melanomas, there were 37 melanomas located in areas of
chronic sun exposure (27 in the head/neck and 10 in the
forearm), 78 melanomas located in areas of intermittent sun
exposure (45 in the thorax, 8 in the upper arm, and 25 in the
legs), 2 anal melanomas (no sun exposure), 23 acral
melanomas, and 1 melanoma of unknown location. All
melanomas from sites with chronic sun exposure (head/
neck and forearm) had marked solar elastosis microscopi-
cally. All cases were classified according to the pTNM
classification (UJCC, 6th edition, 2003). The stages of skin
and primary mucosal tumors were pTis in 6, pT1a in 32,
pT1b in 3, pT2a in 27, pT2b in 4, pT3a in 23, pT3b in 14,
pT4a in 12, and pT4b in 29. The subtypes of the primary
tumors were as follows: superficial spreading (82), nodular
(46), lentigo maligna (5), and acral lentiginous (17). The
pT stages of the uveal melanomas were pT1a in 3, pT1b in
1, pT2a in 25, pT2b in 27, pT2c in 6, pT3 in 15, and pT4 in
20. pT stage could not be determined in three uveal
melanomas. Histologically, a spindle-cell type was present
in 50, an epitheloid type in 13, and a mixed type in 37 cases
of uveal melanomas. All slides from all tumors were
reviewed by one of two pathologists (K.G. for non-uveal
melanomas and P.M. for uveal melanomas) to define the
histological tumor type and the pathological stage.
A semiautomated arraying instrument was used for
TMA construction as described [36]. A representative
tissue cylinder of the vertical growth phase was taken for
the tissue array from primary tumors in the vertical growth
phase (119) and of the radial growth phase from primary
tumors in the radial growth phase (22). Of the 25 skin
melanomas and 40 uveal melanomas, two tissue cores from
the same tumor block were placed in the tissue array.
Tissue samples were collected during 1985–2002 at our
institution. The use of the archival material and data in
research was approved by the Ethics Committee of the
University Hospital Basel.
Fluorescence in situ hybridization
A set of 4-μm TMA sections was used for two-color
fluorescence in situ hybridization (FISH). For the proteo-
lytic slide pretreatment, a commercial kit was utilized
(Paraffin pretreatment reagent kit, Vysis, Downers Grove,
IL, USA). Spectrum Orange-labeled CCND1, MDM2,
MYC, and HER2 were used in combination with Spectrum
Green-labeled chromosomes 11, 12, 8, and 17 centromeric
probes as a reference. All locus-specific probes were
obtained from Vysis, IL, USA. Before hybridization, the
sections were deparaffinized, air dried, and dehydrated in
70, 85, and 100% ethanol followed by denaturation for
5 min at 74°C in 70% formamide–2× SSC solution. After
overnight hybridization at 37°C in a humidified chamber,
slides were washed and counterstained with 0.2 μM DAPI
in an anti-fade solution. For each tumor, the predominant
gene and centromere copy numbers were estimated. A
tumor was considered amplified if the ratio of gene probe
to centromere probe was ≥2.0.
Statistical analysis
Contingency table analysis and chi-square tests were used
to study frequency comparisons of nominal categorized
variables.
Results
FISH analysis was successful for CCND1 in 293 (79%), for
MDM2 in 301 (81%), for MYC in 271 (73%), and HER2 in
322 (87%) out of the 372 melanoma samples. Non-
informative samples were mainly caused by insufficient
hybridization, too high background, or absence of tumor
cells on arrayed tissues.
CCND1
CCND1 amplifications were found in 8% of 120 primary
skin and mucosal melanomas and in 11.2% of 107
metastases from skin melanomas but in none of the 83
uveal melanomas. Among the 21 amplified cases, there
were eight tumors with high-level amplifications showing
>10 CCND1 signals per tumor cell (Fig. 1). The
associations with localization, metastases, and stage are
shown in Table 1. It ia interesting that CCND1 amplifica-
tion was significantly more frequent in acral melanomas
and melanomas of the forearm and the head and neck
(chronic sun exposure) than in melanomas of the trunk, the
legs, and the upper arms (intermittent sun exposure,
p=0.001). All melanomas from chronically sun-exposed
sites with CCND1 amplifications showed moderate to
severe solar elastosis. As lentigo maligna melanomas arise
in chronically sun-damaged skin, CCND1 amplifications
were more frequent in this subtype than in superficial
spreading or nodular melanomas.
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MYC
An increase of MYC gene copies was frequently observed
in uveal (45.1% of 71) and mucosal (62.5% of 8)
melanomas but only rarely in melanomas from sites with
intermittent sun exposure (9% of 67) and not from sites
with chronic sun exposure or acral sites. In most cases with
increased MYC signals, there were only low-level MYC
gene copy number gains with the ratio of MYC copies as
compared to centromere 8 being 2:1. Clear-cut high-level
MYC amplifications with an average ratio of MYC signals
per centromere 8 above 5 and the signals occurring in
distinct clusters was found in four tumor samples: a nodular
melanoma of the upper arm, a nodular melanoma of the
elbow, an esophageal melanoma, and a subcutaneous
metastasis of a substernal primary. The esophageal mela-
noma was the only tumor in this study showing high-level
amplifications of two genes (CCND1 in addition to MYC).
There was an association between MYC copy number
increase and increased tumor stage when all stages were
compared (p=0.018). MYC alterations were significantly
more frequent in melanomas from the nodular than the
superficial spreading type (p=0.002).
MDM2
MDM2 amplifications were found in 3.6% of 139 primary
tumors of the skin but not in metastases nor uveal
melanomas. Two of five amplified tumors had high-level
amplifications (>10 MDM2 copies per cell, Fig. 1). Both
were acral melanomas (Table 1).
HER2
One primary tumor from the back skin (Breslow 0.98 mm,
pT2) showed a low-level amplification of the HER2 gene
(two centromere and five HER2 copies per cell). All the
other 322 interpretable primary melanomas and metastases
showed no HER2 amplifications.
Results of multiple samples from one patient
For CCND1, MDM2, and HER2, all multiple samples from
the same patient showed a consistent result. Among these
multiple samples, there were four concordant amplifica-
tions of the CCND1 gene [multiple metastases (2×),
samples of the same tumor block (1×), and a primary tumor
of the esophagus with its lymph node metastasis].
The evaluation of the MYC gene revealed some
discrepant results in multiple samples of the same patient.
In five uveal melanomas and one skin melanoma, one
tissue cylinder had low-level MYC gene copy number
gains while the other cylinder of the same tumor block
showed a normal MYC copy number as a result of
intratumoral heterogeneity. The primary tumor of an
esophageal melanoma but not its corresponding lymph
node metastasis had a high-level MYC amplification. In
another 45 cases with multiple tissue cylinders from one
patient, the results of MYC copy numbers of all samples
were congruent. Of these 45 cases, 24 had an increased
MYC copy number.
Discussion
In this study, the analysis of 372 melanoma tissue samples
revealed significant molecular differences between tumors
of different sites.
FISH was used to investigate gene amplifications of
CCND1, MDM2, MYC, and HER-2. Among these genes,
high-level amplifications of CCND1 were most frequent. It
is interesting that CCND1 amplification was significantly
more frequent in locations with chronic sun exposure
(head/neck and forearms) than in locations with intermit-
tent sun exposure (trunk, legs, and upper arms), raising the
Fig. 1 a CCND1 amplification in a lentigo maligna melanoma.
Hybridization was done with probes for centromere 11 (green) and
CCND1 (red). Large tumor cells in the lower half of the image
contain one or two irregularly formed clusters consisting of many
closely packed red CCND1 signals and up to four centromere 11
signals. ×640 magnification. b MDM2 high-level amplification in
acral lentiginous melanoma. Hybridization was done with probes for
centromere12 (green) and MDM2 (red). Large tumor cells with
several clusters of MDM2 signals. ×640 magnification
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possibility that CCND1 activation could be particularly
important for melanoma development in sites with chronic
sun exposure. Our overall frequency and site distribution of
CCND1 amplifications in primary skin melanomas is
consistent with previous data [12, 34].
The presence of frequent CCND1 amplifications in acral
melanomas could be explained by an overall higher level of
genetic instability of these tumors involving other molec-
ular pathways than in classical skin melanoma [5, 12].
Our mucosal melanoma with CCND1 amplification had
originated from the esophagus where CCND1 amplifica-
tion occurs at a particularly high frequency in carcinomas
as well [35]. A review of our case confirmed the melanoma
diagnosis, however. In the same tumor, we additionally
detected a high-level MYC amplification illustrating the
higher degree of genetic instability in mucosal melanomas
[12].
MDM2 was only amplified in five melanomas including
two high-level amplifications. Both high-level amplifica-
tions were seen in acral melanomas. This finding and the
overall low number of MDM2 amplifications are consistent
with previous data from Bastian et al. [3]. They found
12q14 copy number gains in 5 of 22 acral melanomas but
none in 108 non-acral skin melanomas using CGH and
MDM2 amplifications in 1 of 15 acral melanomas by
FISH.
Amplifications in acral melanomas but not in non-acral
melanomas have been shown to be present in the in situ
portion and in the invasive areas at mostly similar levels [2,
3]. It was concluded that the amplifications arise very early
during tumor progression in acral melanomas, suggesting
that acral melanomas develop a specific amplification-
permissive defect early in tumorigenesis unique to the
pathogenesis of this tumor type [3, 5]. In most cancers,
gene amplifications occur frequently at a late stage and are
clearly associated with tumor progression though the
mechanisms through which amplifications are generated
are largely unknown [23]. The fact that amplifications, in
general, occur late in tumorigenesis may explain why
amplifications are rather frequent in mucosal melanomas
[12] which are usually diagnosed at a late stage.
The unique molecular features in uveal melanomas are
not unexpected due to their special location. The chromo-
somes 1, 3, 6, and 8 are consistently affected by non-
random aberrations mainly in the form of chromosomal
gains and losses [18, 38]. Additional copies of the long arm
of chromosome 8 either by translocation or in the form of
an isochromosome i(8q) have been shown to correlate with
reduced survival [25]. Parrella et al. [27] had described
MYC amplification in 14 of 43 uveal melanomas. These
amplifications were of borderline nature typically showing
twice as many MYC copies as compared to centromere 8 in
FISH analysis. Twice as many gene copies as centromere
copies typically reflect a duplication of a large stretch of
DNA (e.g., isochromosome formation) rather than a gene-
specific amplification event as has been shown in studies of
uveal and skin [22, 39] melanomas. By CGH analysis,
over-representation of the long arm of chromosome 8 has
been reported in 38% of primary melanomas [4]. The poor
prognosis associated with extra copies of chromosome 8q
may point to the presence of several oncogenes in this
region. Ehlers et al. [16] suggest that the DDEF1 gene
Table 1 Molecular findings, tumor phenotype, stage, and location
CCND1 (%) MDM2 (%) MYC (%) HER2 (%)
Localization of primary tumor Uvea 0/83 0/59 32/71 (45.1) 0/78
Intermittent sun exposure 0/65 3/72 (4.8) 6/67 (9) 1/66 (1.5)
Chronic sun exposure 6/32 (18.8)a 0/32 0/24 0/33
Acral 4/17 (23.5)b 2/19 (10.5) 0/9 0/19
Mucosa 1/10 (10) 0/8 5/8 (62.5) 0/9
pT (skin primary tumors) pT1 1/24 (4.2) 3/27 (11.1) 0/25 1/21 (4.8)
pT2 2/25 (8.0) 0/26 1/25 (4) 0/28
pT3 3/32 (9.4) 1/34 (2.9) 4/29 (13.8) 0/33
pT4 5/33 (15.2) 1/32 (3.1) 6/23 (26.1)c 0/34
Metastases Lymph node 8/65 (12.3) 0/60 3/92 0/66
Distant 5/43 (11.6)d 0/46 3/92 0/43
Growth phase Radial 0/18 1/17 (5.9) 0/17 0/21
Vertical 11/101 (10.9) 4/107 (3.7) 7/92 (12.0) 1/102 (1.0)
Histologic subtype Superficial spreading 3/70 (4.3) 3/71 (4.2) 2/67 (6.0) 1/71 (1.4)
Nodular 3/39 (7.7) 0/37 7/31 (22.6)e 0/38
Lentigo maligna 2/4 (50) 0/5 0/3 0/5
Acral lentiginous 3/12 (25) 2/13 (15.4) 0/8 0/14
Tumors with CCND1, MDM2, MYC, and HER2 gene probe to centromere probe ratio ≥2.0 detected by FISH. Percentages are indicated in
brackets
aSite of chronic sun exposure (head/neck and forearm) vs site of intermittent sun exposure (upper arm, leg, and trunk), p<0.0001
bAcral vs non-acral skin, p=0.02
cMYC copy number increases when all stages are compared, p=0.018
dPrimary tumors vs metastases, p<0.0001
eNodular vs superficial spreading type, p=0.002
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located at 8q24 rather than MYC which is also located at
8q24 may function as an oncogene during uveal melanoma
progression. The fact that the copy number alterations of
the MYC gene are more common in advanced tumors of
the nodular subtype has been shown before in studies with
limited case numbers [22, 40]. Blocking the expression of
MYC with liposomal MYC antisense oligodeoxynucleo-
tides has been reported to inhibit tumor growth and
metastases in an in vivo melanoma model [28]. Hopefully,
such an approach will finally provide a targeted therapy for
selected patients with advanced melanomas.
One skin melanoma showed HER2 amplification
according to our definition. This case had two centromere
and five HER2 signals which do not constitute a classical
amplification. Persons et al. [30] have also reported one
HER2 amplification in 40 advanced melanomas. It is not
surprising that several studies have proposed HER2
overexpression in up to 80% of melanomas [6, 26] as
IHC can yield highly variable results under non-stan-
dardized conditions. More recent IHC studies using Food
and Drud Administration-approved reagents have de-
scribed inexistent [17] or a very low rate of detectable
HER2 expression (0.9–3%) [19, 31] (own unpublished
findings). Altogether, these data strongly argue against a
possible therapeutic application of Herceptin in malignant
melanoma.
The hypothesis of distinct genetic alterations between
melanomas arising in different sites is also supported by the
results of recent studies on the frequency of BRAF
mutations. BRAF mutations have been observed preferen-
tially in melanomas from skin without chronic sun-induced
damage [12] but only rarely or not at all in acral
melanomas, melanomas from chronically sun-exposed
skin, and mucosal and uveal melanomas [10, 15, 24, 33].
The comparison of aberration frequencies in CGH analysis
of melanomas with different sun exposure patterns
revealed significant differences between the subgroups
defined by location [12, 34]. Altogether, there is increasing
evidence for site-specific molecular pathways of melanoma
development.
As we know from H&E morphology, malignant
melanomas often show considerable intratumoral hetero-
geneity. On several occasions, this heterogeneity has also
been observed at the molecular level [4, 8, 32]. TMAs
provide a method for the rapid and simultaneous analysis
of up to 1,000 tissue samples in a single experiment under
highly standardized conditions. They are not intended for
making clinical diagnoses of individual cases but to screen
for molecular alterations. The validity of TMA analysis has
been shown by comparisons with whole-section analysis in
breast, prostate, and brain cancer [20].
In a limited number of cases, we had analyzed more than
one sample from the same patient revealing a low number
of discordant results. It is interesting that, in one case, a
high-level MYC amplification was present in the esoph-
ageal primary tumor but not in its lymph node metastasis.
A more detailed study of intratumoral heterogeneity will be
especially important for the evaluation of potential thera-
peutic targets that should be present throughout the whole
tumor and in its metastases if targeted therapy is to be
effective. For that purpose, whole-section slides or several
samples of different areas within a given tumor, e.g., of the
vertical and radial growth phases, will have to be analyzed.
Due to their genetic characteristics, melanomas may
respond differently to various cytotoxic and biologic
cancer therapies depending on their body location and
the presence or absence of chronic sun-induced damage.
The latter can roughly be estimated microscopically by the
degree of solar elastosis. In future studies that investigate
the molecular pathogenesis of malignant melanomas and in
clinical trials with new drug targets, the genetic diversity of
melanomas from different sites should be taken into
account.
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